AMRX Stock Cash Flow Statements

Amneal Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Amneal Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31

cash flows from operating activities:
net income	24,618,000	-20,742,000	11,757,000	16,787,000	-81,678,000	29,683,000	-10,094,000	-5,858,000	-2,390,000	-240,081,000	-6,460,000	-20,459,000	-6,092,000	32,176,000	14,545,000	-6,962,000	-22,033,000	-23,944,000	121,517,000	-64,903,000	-363,392,000	-50,526,000	-124,752,000	-20,330,000	17,465,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	60,159,000	66,130,000	58,961,000	55,572,000	55,528,000	57,111,000	58,150,000	61,056,000	61,608,000	59,696,000	57,815,000	61,183,000	60,186,000	56,488,000	55,549,000	59,873,000	59,359,000	58,072,000	58,083,000	54,303,000	53,358,000	50,706,000	48,868,000	47,493,000	43,013,000
unrealized foreign currency (gain) loss	-3,596,000					426,000	-1,987,000								-1,970,000	-8,949,000
amortization of debt issuance costs and discount	6,811,000	26,435,000	1,441,000	933,000	288,000	2,465,000	2,058,000	2,106,000	2,101,000	2,193,000	2,195,000		2,400,000	2,290,000	2,183,000		2,235,000	2,210,000	2,004,000
reclassification of cash flow hedge	-6,444,000
intangible asset impairment charges		0	0	0	920,000			18,295,000	674,000			22,004,000	688,000			1,720,000	32,364,000	759,000	2,416,000	14,171,000	79,514,000	3,012,000	76,084,000	39,454,000
stock-based compensation	7,258,000	7,210,000	7,112,000	6,724,000	6,722,000	6,561,000	7,596,000	7,831,000	7,689,000	8,262,000	8,065,000	7,742,000	7,708,000	7,632,000	5,330,000		5,415,000	5,663,000	4,539,000
inventory provision	23,669,000	32,947,000	22,118,000	18,570,000	22,923,000	16,602,000	25,204,000	22,212,000	11,136,000	14,170,000	3,578,000	15,370,000	13,485,000	9,784,000	16,021,000	19,038,000	21,490,000	19,508,000	15,200,000	14,401,000	17,434,000	34,760,000	15,650,000	23,784,000	3,329,000
other operating charges and credits	1,313,000	2,503,000	1,481,000	-2,781,000	1,250,000	1,317,000	2,047,000	1,751,000	3,628,000	2,294,000	1,155,000	1,668,000	1,201,000	1,333,000	1,431,000	5,570,000	2,092,000	2,890,000	1,266,000	1,364,000	2,790,000	2,046,000	1,109,000	89,000
changes in assets and liabilities:
trade accounts receivable	21,148,000	-28,606,000	21,812,000	-100,670,000	-55,173,000	-128,994,000	195,970,000	-113,287,000	60,131,000	-150,829,000	124,268,000	-34,515,000	24,061,000	-121,552,000	108,385,000	67,535,000	-126,517,000	136,662,000	-60,893,000	-86,269,000	116,497,000	2,058,000	-165,012,000	163,795,000	-14,660,000
inventories	-13,263,000	-51,985,000	-43,098,000	-23,247,000	-12,200,000	-38,018,000	-22,508,000	-11,070,000	-25,931,000	-39,846,000	-25,549,000	16,628,000	-11,063,000	-34,297,000	-20,283,000	-33,060,000	-47,540,000	-30,404,000	-2,778,000	5,513,000	-6,248,000	-5,478,000	-14,180,000	10,833,000	17,947,000
prepaid expenses, other current assets and other assets	-513,000	1,123,000	6,336,000	3,290,000	-11,708,000	2,738,000	29,160,000	44,262,000	85,367,000	-115,324,000	-4,423,000	5,512,000	-3,505,000	-24,590,000	602,000	15,674,000	8,866,000	35,155,000	-26,383,000	-2,386,000	12,642,000	5,957,000	22,657,000	9,395,000
related party receivables	-2,000	965,000	145,000	-66,000	-562,000	-119,000	470,000	1,163,000	-358,000	-163,000	4,000	110,000	-182,000	7,082,000	301,000	-458,000	237,000	557,000	76,000	366,000	319,000	-1,310,000	-314,000	100,000
accounts payable, accrued expenses and other liabilities	-112,626,000	66,256,000	46,853,000	59,852,000	62,174,000	42,723,000	-150,483,000	-55,869,000	-108,510,000	322,724,000	-48,777,000	-11,113,000	-11,682,000	16,089,000	-37,226,000	-21,430,000	6,565,000	-19,667,000	34,839,000	3,675,000	-394,000	-14,233,000	695,000	-28,354,000
related party payables	-1,124,000	34,102,000	10,720,000	4,124,000	5,495,000	1,241,000	1,672,000	-407,000	-5,029,000	2,376,000	5,132,000	1,632,000	-75,000	-7,172,000	3,260,000	45,000	1,740,000	-3,834,000	3,695,000	5,203,000	-2,200,000	1,569,000	656,000	12,000
net cash from operating activities	7,408,000	118,078,000	141,774,000	39,657,000	-4,410,000	-11,345,000	139,712,000	-23,292,000	93,570,000	-125,521,000	120,343,000	63,261,000	82,364,000	-51,933,000	148,128,000	105,958,000	44,776,000	179,241,000	49,026,000	-50,889,000	139,910,000	21,094,000	-108,410,000	259,651,000	62,129,000
capex	-13,162,000	-15,155,000	-16,945,000	-10,626,000	-9,198,000	-12,003,000	-9,688,000	-11,466,000	-19,099,000	-5,049,000	-10,793,000	-17,498,000	-10,645,000	-7,809,000	-11,776,000	-29,533,000	-10,993,000	-8,552,000	-7,367,000	-4,517,000	-13,035,000	-11,641,000	-17,988,000	-20,023,000	-26,465,000
free cash flows	-5,754,000	102,923,000	124,829,000	29,031,000	-13,608,000	-23,348,000	130,024,000	-34,758,000	74,471,000	-130,570,000	109,550,000	45,763,000	71,719,000	-59,742,000	136,352,000	76,425,000	33,783,000	170,689,000	41,659,000	-55,406,000	126,875,000	9,453,000	-126,398,000	239,628,000	35,664,000
cash flows from investing activities:
purchases of property, plant and equipment	-13,162,000	-15,155,000	-16,945,000	-10,626,000	-9,198,000	-12,003,000	-9,688,000	-11,466,000	-19,099,000	-5,049,000	-10,793,000	-17,498,000	-10,645,000	-7,809,000	-11,776,000	-29,533,000	-10,993,000	-8,552,000	-7,367,000	-4,517,000	-13,035,000	-11,641,000	-17,988,000	-20,023,000	-26,465,000
acquisition of intangible assets	-4,200,000	-600,000	-3,600,000	-750,000	-9,700,000	-1,150,000	-338,000	0	-31,800,000				0			-1,100,000	-2,200,000	0	-1,050,000
deposits for future acquisition of property, plant and equipment	-960,000		-167,000	-78,000	-862,000
proceeds from sale of property, plant and equipment	524,000
net cash from investing activities	-17,798,000	-16,059,000	-20,712,000	-6,465,000	-19,760,000	-12,284,000	-11,737,000	-11,466,000	-49,332,000	-16,116,000	-97,395,000	-86,969,000	-11,633,000	-82,887,000	-12,693,000	-31,795,000	-14,782,000	-8,927,000	-262,042,000	-4,767,000	29,982,000	-23,329,000	-21,466,000	5,321,000	-40,775,000
cash flows from financing activities:
payments of principal on debt, revolving credit facilities, financing leases and other	-235,528,000		-54,506,000	-15,500,000	-63,377,000
borrowings on revolving credit facilities	218,000,000		0	0	48,000,000
proceeds from exercise of stock options	69,000	151,000	617,000	358,000	28,000			0	423,000	128,000	111,000	19,000	153,000	5,000	676,000	105,000	58,000	153,000	5,000	15,000	0	375,000	1,010,000	635,000
employee payroll tax withholding on restricted stock unit and performance stock unit vesting	-21,639,000
tax distributions to non-controlling interests	-68,000		-5,559,000	-8,289,000	-594,000	-17,338,000	-18,219,000		-3,214,000	-6,753,000	-3,164,000		-9,127,000				-3,201,000
net cash from financing activities	-39,166,000	-61,204,000	-92,346,000	-35,086,000	-23,155,000	-12,256,000	-12,900,000	-22,167,000	-46,132,000	23,249,000	-61,570,000	-30,350,000	-43,555,000	-38,068,000	-26,149,000	-11,282,000	-14,808,000	-310,082,000	467,979,000	-7,298,000	-7,596,000	-9,075,000	-21,864,000	-218,920,000	82,600,000
effect of foreign exchange rate on cash	-470,000	-740,000	7,000	-101,000	-165,000	-602,000	767,000	-3,739,000	-397,000	25,000	-1,572,000	178,000	290,000	227,000	-593,000	590,000	192,000	1,115,000	-860,000	-1,282,000	-2,260,000	1,589,000	-296,000	534,000	-351,000
net decrease in cash, cash equivalents, and restricted cash	-50,026,000								-2,291,000													-9,721,000	-152,036,000
cash, cash equivalents, and restricted cash - beginning of period	118,420,000	0	0	0	99,107,000	0	35,227,000	0	0	0	256,739,000	0	0	0	347,121,000	0	0	0	152,822,000	0	0	0	218,779,000	0	0
cash, cash equivalents, and restricted cash - end of period	68,394,000	40,075,000	28,723,000	-1,995,000	51,617,000	-36,487,000	151,069,000	-60,664,000	-2,291,000	-118,363,000	216,545,000	-53,880,000	27,466,000	-172,661,000	455,814,000	63,471,000	15,378,000	-138,653,000	406,925,000	-64,236,000	160,036,000	-9,721,000	66,743,000	46,586,000	103,603,000
cash and cash equivalents - end of period	59,187,000	36,546,000	30,237,000	-2,751,000	46,520,000	-35,390,000	144,674,000	-61,359,000	-4,644,000	-118,498,000	210,477,000	-54,865,000	24,349,000	-173,791,000	452,097,000	60,100,000	15,135,000	-139,095,000	405,238,000	-61,541,000	157,845,000	-9,053,000	63,946,000	48,202,000	103,671,000
restricted cash - end of period	6,583,000	3,529,000	-1,514,000	756,000	5,097,000	-1,097,000	6,395,000	695,000	2,353,000	135,000	6,068,000	985,000	3,117,000	1,130,000	3,717,000	3,371,000	243,000	442,000	1,687,000	-2,695,000	2,191,000	-668,000	2,797,000	-1,616,000	-68,000
long-term restricted cash included in other assets - end of period	2,624,000
unrealized foreign currency gain				569,000	1,511,000						3,140,000												6,490,000	-2,978,000	4,528,000
loss on refinancing									0
change in fair value of contingent consideration		0	-1,030,000	0	100,000	-6,364,000	2,457,000	2,226,000	-1,425,000	-270,000	200,000	-100,000
insurance recoveries for property and equipment losses								0	0
deposits for future acquisition of property, plant, and equipment							-1,711,000	0	1,567,000	-2,067,000	-1,888,000	-556,000	-988,000	-750,000	-917,000	-1,162,000
acquisitions of business
proceeds from insurance recoveries for property and equipment losses								0	0
proceeds from sale of subsidiary		7,005,000	0
payments of deferred financing, refinancing costs and debt extinguishment costs
payments of principal on debt, revolving credit facility, financing leases and other							-72,659,000	-17,654,000
proceeds from issuance of debt																0	0	0	180,000,000					0	0
borrowings on revolving credit facility							80,000,000	0	0
employee payroll tax withholding on restricted stock unit vesting		-387,000	-194,000	-159,000	-7,212,000	-11,000	-2,022,000	-88,000	-192,000	-290,000	-3,001,000	-69,000	-217,000	-276,000	-2,102,000	-68,000	-238,000	-54,000	-503,000	0	-5,000
payments of deferred consideration for acquisitions - related party								0	-500,000	0	-43,998,000
acquisition of redeemable non-controlling interests
tax distributions to non-controlling interest
repayment of related party note													0	0	-1,000,000										0
net increase in cash, cash equivalents, and restricted cash		40,075,000	28,723,000	-1,995,000	-47,490,000	-36,487,000	115,842,000				-40,194,000	-53,880,000	27,466,000	-172,661,000	108,693,000	63,471,000	15,378,000	-138,653,000	254,103,000	-64,236,000				46,586,000	103,603,000
payments of deferred financing and refinancing costs								0	-41,000
payment of principal on notes payable - related party			-32,704,000
non-cash property losses
acquisitions of businesses, net of cash acquired								0	0
payments of principal on financing lease - related party												0	0	0	-93,000	-277,000	-272,000	-267,000	-263,000	-563,000	-841,000	-247,000	-619,000
loss on refinancing - revolving credit facility
saol acquisition
acquisition of redeemable non-controlling interest									0	0	-1,722,000													0
acquisition of business											-84,714,000
gain on sale of international businesses																	0
non-cash restructuring and asset-related (benefit) charges
distribution of earnings to and acquisition of non-controlling interest
unrealized foreign currency loss									4,879,000				-218,000						5,514,000
payments of principal on debt, financing leases and other										-53,214,000	-9,796,000	-9,846,000	-34,364,000	-10,246,000	-23,630,000	-9,433,000	-9,428,000
supplemental disclosure of cash flow information:
cash paid for interest											27,289,000	30,069,000	30,237,000	31,524,000	29,917,000	30,979,000	30,774,000	33,047,000	35,386,000	36,696,000	40,769,000	41,071,000	40,032,000	42,430,000	38,684,000
cash paid for income taxes											4,387,000			3,877,000	733,000
supplemental disclosure of non-cash investing and financing activity:
contingent consideration for acquisition											8,796,000
gain from reduction of tax receivable agreement liability																				0
amortization of levothyroxine transition agreement asset																				0	0	0	36,393,000
amortization of debt issuance costs																				1,629,000	1,631,000	1,617,000	1,601,000	1,639,000	1,643,000
deferred tax provision																				33,000					5,882,000
non-cash property and equipment losses
acquisition of product rights and licenses																				-250,000	0			0	-11,000,000
acquisitions, net of cash acquired												-72,715,000	0			0	2,640,000	-375,000	-253,625,000					0	-3,310,000
proceeds from sale of international businesses, net of cash sold																				0	0
payments of deferred financing costs and debt extinguishment costs																								0	0
tax distribution to non-controlling interest																				0	0	0	-13,494,000	-71,086,000
repayment of related party notes
cash (paid) received for income taxes												-3,975,000						-1,088,000	-3,430,000
notes payable for acquisitions - related party																0	0	0	36,033,000
deferred consideration for acquisition - related party												0	0
contingent consideration for acquisition - related party												-400,000	0
payable for acquisition of product rights and licenses												-1,200,000											50,000,000
asset-related credit
payments of deferred financing costs																	0	0	-4,102,000
distribution of earnings to and acquisition of non-controlling interests
payments for restricted stock unit tax vesting
income taxes receivable associated with the cares act																		0	-110,069,000
tax distribution to non-controlling interests															9,757,000
net borrowings on revolving credit facility																			300,000,000
loss on extinguishment of debt																								0
(gain) loss on sale of international businesses																				-328,000
non-cash restructuring and asset-related charges																				536,000	10,609,000
stock-based compensation and ppu expense																				5,013,000	6,095,000			3,606,000	3,590,000
proceeds from surrender of corporate owned life insurance																				0
proceeds from sales of property, plant and equipment
net payments on revolving credit line
payments of principal on financing obligation - related party
equity contributions																								0	0
capital contribution from non-controlling interest																									0
distributions to members																								0	0
cash received for income taxes																-9,303,000
acquisition of non-controlling interest																				0	0	-1,532,000	-2,011,000
distribution to members																								0	0
asset classification
buildings
computer equipment
furniture and fixtures
leasehold improvements
machinery and equipment
vehicles
non-cash restructuring and asset-related (credit) charges
deferred tax benefit																						-8,325,000	-9,884,000
gain on sale of international business																							-8,818,000
cash sold with international business																							-3,478,000
payments of principal on debt and financing leases																			-7,158,000
receivable from the sale of international business																							35,837,000
payments of principal on debt and capital leases																				-6,750,000	-6,750,000	-6,750,000	-6,750,000
net (payments) borrowings on revolving credit line
capital contribution from (dividend to) non-controlling interest
cash received (paid), net for income taxes
receivable from the sale of international businesses
note payable resulting from the ireland building purchase
transaction costs paid by amneal holdings
net borrowings on revolving credit line
cash received (paid) for income taxes																							9,713,000
gain on termination of lease
payments on revolving credit line
payments of financing obligation - related party
stock-based compensation expense																							4,347,000
loss on sale of certain international businesses																								146,000
proceeds from sale of certain international businesses, net of cash sold
receivable from the sale of certain international businesses
transaction costs paid by amneal holdings, llc
investing activities:
financing activities:
payments of principal on debt, financing obligations and capital leases
income taxes paid
loss on extinguishment and modification of debt
gain termination of lease
allowance for doubtful accounts provision
other
prepaid expenses and other current assets
related-party receivables
other assets
accounts payable and accrued expenses
other liabilities
related-party payables
payments on capital leases
payments on financing obligations
payments on debt
exercise of stock options
other current assets and current liabilities
net change in cash and cash equivalents
cash and cash equivalents at the beginning of period
cash and cash equivalents at the end of year

We provide you with 20 years of cash flow statements for Amneal Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Amneal Pharmaceuticals stock. Explore the full financial landscape of Amneal Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Amneal Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.